- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Automatic Translation feature is available on CiNii Labs
- Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2– breast cancer
-
- Aditya Bardia
- Massachusetts General Hospital Cancer Center, Boston, MA, USA
-
- Komal Jhaveri
- Memorial Sloan Kettering Cancer Center, New York, NY, USA
-
- Kevin Kalinsky
- Winship Cancer Institute at Emory University, Atlanta, GA, USA
-
- Sonia Pernas
- Institut Català d’Oncologia, IDIBELL, L’Hospitalet, Barcelona, Spain
-
- Junji Tsurutani
- Showa University Hospital, Tokyo, Japan
-
- Binghe Xu
- National Cancer Center / National Clinical Research Center for Cancer / Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
-
- Erika Hamilton
- Sarah Cannon Research Institute / Tennessee Oncology, Nashville, TN, USA
-
- Seock-Ah Im
- Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University, Seoul, Republic of Korea
-
- Zbigniew Nowecki
- Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
-
- Joohyuk Sohn
- Yonsei University College of Medicine, Seoul, Republic of Korea
-
- Michelino De Laurentiis
- Istituto Nazionale Tumori Napoli IRCCS “Fondazione Pascale”, Napoli, Italy
-
- Noelia Martínez Jañez
- Ramón y Cajal University Hospital, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain
-
- Barbara Adamo
- August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Hospital Clinic, University of Barcelona, Barcelona, Spain
-
- Keun Seok Lee
- Center for Breast Cancer, National Cancer Center, Goyang, Republic of Korea
-
- Kyung Hae Jung
- Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
-
- Gábor Rubovszky
- National Institute of Oncology, Budapest, Hungary
-
- Ling-Ming Tseng
- Comprehensive Breast Health Center, Taipei Veterans General Hospital, Taipei, Taiwan
-
- Yen-Shen Lu
- National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan
-
- Yuan Yuan
- Formerly City of Hope Comprehensive Cancer Center, Duarte, CA, USA; Currently: Cedars-Sinai Cancer Center, Los Angeles, CA, USA
-
- Micah J Maxwell
- AstraZeneca, Gaithersburg, MD, USA
-
- Vincent Haddad
- AstraZeneca, Cambridge, UK
-
- Sabrina S Khan
- AstraZeneca, Gaithersburg, MD, USA
-
- Hope S Rugo
- University of California San Francisco Comprehensive Cancer Center, San Francisco, CA, USA
-
- Barbara Pistilli
- Gustave Roussy Cancer Center, Villejuif, France
Search this article
Description
Improving the prognosis for patients with metastatic HR+/HER2- breast cancer remains an unmet need. Patients with tumors that have progressed on endocrine therapy and/or are not eligible for endocrine therapy had limited treatment options beyond chemotherapy. Antibody-drug conjugates are a novel and promising treatment class in this setting. Datopotamab deruxtecan (Dato-DXd) consists of a TROP2-directed humanized IgG1 monoclonal antibody attachedAntibody-drug conjugates are a type of drug with two parts: an antibody that directs the drug to the cancer cells and a cancer-cell killing toxic payload. By binding to cancer cells before releasing the payload, treatment is directed to the site of action so there are fewer side effects in the rest of the body. Datopotamab deruxtecan (Dato-DXd) is an antibody-drug conjugates made up of datopotamab (antibody) and DXd (payload) which are joined together
Journal
-
- Future Oncology
-
Future Oncology 20 (8), 423-436, 2023-06-30
Informa UK Limited
